Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. (NASDAQ: HBIO) on July 16, 2025. The filing discloses significant changes to the Company's executive leadership and Board of Directors, including the resignation of the Chief Executive Officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- CEO Departure: James W. Green resigned as President, Chief Executive Officer, and Chairman of the Board. His resignation as CEO and Chairman is effective July 28, 2025, with his final day as an employee and Board member on August 15, 2025. The resignation is not due to any disagreement with the Company.
- CEO Appointment: John Duke was appointed President and Chief Executive Officer, effective July 28, 2025. Mr. Duke previously served as CEO of Plastic Molding Technology and held senior roles at Lyten and Corning Incorporated.
- Board Elections: Robert Gagnon and Seth Benson were appointed to the Board. Mr. Gagnon was named Chair of the Audit and Compensation Committees. Mr. Benson was appointed to the Audit Committee.
- Director Compensation Reduction: The annual retainer for non-employee directors was reduced from $190,000 to approximately $135,000, consisting of a $91,000 cash retainer and 110,000 restricted stock units.
Guidance, Outlook, and Compensation Details
The filing outlines the new employment agreement for CEO John Duke, effective July 16, 2025:
- Base Salary: $480,000 annually, subject to review starting in 2026.
- Cash Incentive: Eligible for up to 80% of base salary based on objectives.
- Equity Grants (2026 Target): Anticipated target value of $1,036,000.
- Initial Equity Awards:
- 500,000 Restricted Stock Units (RSUs) vesting in three equal annual installments.
- 500,000 target share amount of market condition deferred stock awards (RSUs) vesting based on relative Total Shareholder Return (TSR) versus the Russell 2000 over three years.
- Severance: Provisions for termination without cause, for good reason, or in connection with a change-in-control, including potential acceleration of vesting.
The filing does not provide specific financial guidance or operational outlook beyond the leadership transition.
Investor Verification Checklist
- Verify the effective dates of the CEO transition (July 28, 2025) and the final departure of the former CEO (August 15, 2025).
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "good reason," "without cause," and change-in-control triggers.
- Confirm the impact of the reduced director compensation on Board retention and alignment.
- Monitor the Company's stock performance relative to the Russell 2000 to assess the vesting potential of Mr. Duke's performance-based equity awards.
- Check for subsequent filings regarding the interim leadership structure between the announcement and the effective date of the new CEO.